about
Conducting radiogenomic research--do not forget careful consideration of the clinical data.Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy.Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial.Voluntary breath-hold technique for reducing heart dose in left breast radiotherapy.The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trialPushing the limits of hypofractionation for adjuvant whole breast radiotherapy.Hypofractionated whole-breast radiotherapy for women with early breast cancer: myths and realities.Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.Clinical nurse specialists in palliative care. Part 3. Issues for the Macmillan Nurse role.Clinical nurse specialists in palliative care. Part 1. A description of the MacMillan Nurse caseload.Lung cancer health care needs assessment: patients' and informal carers' responses to a national mail questionnaire survey.The UK HeartSpare Study (Stage IB): randomised comparison of a voluntary breath-hold technique and prone radiotherapy after breast conserving surgery.Coping response and survival in breast cancer patients: a new analysis.Ipsilateral breast tumor relapse: local recurrence versus new primary tumor and the effect of whole-breast radiotherapy on the rate of new primaries.A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen.The UK HeartSpare Study: randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy.Menopausal hot flushes after breast cancer.Project 27/28: inquiry into quality of neonatal care and its effect on the survival of infants who were born at 27 and 28 weeks in England, Wales, and Northern Ireland.The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials.Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort.Influence of psychological response on survival in breast cancer: a population-based cohort study.Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation?Patterns of complementary and alternative medicine use among patients undergoing cancer treatment.Integration of patient-reported outcome measures with key clinical outcomes after immediate latissimus dorsi breast reconstruction and adjuvant treatment.Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey.Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.The course of anxiety and depression over 5 years of follow-up and risk factors in women with early breast cancer: results from the UK Standardisation of Radiotherapy Trials (START).Targeted radiotherapy for early breast cancer - Authors' reply.Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial.Prone versus supine positioning for whole and partial-breast radiotherapy: a comparison of non-target tissue dosimetry.The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial).Acute toxicity and 2-year adverse effects of 30 Gy in five fractions over 15 days to whole breast after local excision of early breast cancer.Treatment decisions in older patients with colorectal cancer: the role of age and multidimensional function.First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy.
P50
Q30581922-010B42DD-7A71-4349-8651-848B1F68D80AQ33598555-5F062A45-8D31-4BEE-8083-9B3398647C98Q34270401-12AA2A69-9A01-4F6A-8EFF-2516358F3D6DQ34414425-E19FC050-68E6-441A-829E-AE83A6B41B07Q36514573-F9B1CCDE-C01B-41E6-9884-103D165B51A9Q36571627-34524CB3-5D2E-477D-9D42-D5651C86591FQ37761554-3FFD5B3C-D0C3-40CF-BCE4-F67F5EA7B05AQ37800548-D8779B6D-AC42-4513-AF02-B00A59B3180BQ38909247-5E21C8B5-01D6-4987-9AE3-B772F8CFB2A6Q39200585-6B38D8F6-A2A5-4826-B16F-078AEC296EE5Q39402083-57403557-839D-4D27-9784-371E559F129BQ39404929-D734705F-65AB-4450-B10B-45E2971D2AC8Q39570609-0C2AE930-9694-4589-A6D8-0F0A9DA99259Q41297262-15414EA3-CC45-45C5-A9A6-1C2AD3448BCAQ43474206-D102BFB3-83A1-4144-9C95-B1DA671B0EEAQ43981004-EB6868C1-8C78-430A-9A5F-FF6683FC5C0EQ44727588-12FB42F1-B26E-4578-A2DE-7732B54DAF03Q45749878-2A0D6EF1-F456-4876-96C3-3A2EA14ADCF9Q46097285-80B98839-62CC-4CE1-A7C3-B0B4202FD879Q46342854-81C7F8D1-8DD7-47AC-8E1A-24D5D59DB73DQ46425805-64E8EBDC-217E-4173-94A9-150CEB576D62Q46427630-8D9AC909-8166-43F8-A74E-8E8967E4270FQ46858839-4E62FA52-21E3-499C-8172-D754C219FAD4Q47335209-3407BFD9-8268-40A7-94CE-63735043735DQ47341729-66A01180-4207-4E5E-A26B-EB2B2E0B622EQ47348485-120AE400-5A08-4B8F-9801-E86D36F74D0CQ47392607-CE25772D-2416-4B3D-A5EA-866E81290AE0Q48281409-362E8A43-21AC-45F9-B1C2-7A1CFC5B9C31Q48350028-C986AC0D-7977-40F9-A22F-F3C56AACD6A2Q48544455-FC3C614A-B0CF-4AB6-94E3-7C99BE251322Q48890409-95AF50D3-9A69-4D2E-86BB-BDF7493E50C3Q48919790-C4C0B994-2FEE-4020-BD37-13D12533712DQ50091659-0824F670-2E0A-43D8-960D-78E07BD2E9A8Q50760966-8C49C41C-4AF5-4800-848E-E8DB469DCDF5Q50785251-905DB3D5-6D94-40A5-92F2-12ECFF6D0642Q50912398-A72EFF5F-5F22-45EF-8E50-267798AEE65FQ51118188-8B6D1337-1754-47D5-989E-1E3641BBFD1EQ51947223-5CBCAC15-BDA8-462B-96BA-81F68288DBAEQ53213927-203A3D11-AF81-4FA7-A770-F2EB37765992Q53297385-8E83CC5F-1869-4B43-92CE-D3C631A58842
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joanne Haviland
@ast
Joanne Haviland
@en
Joanne Haviland
@es
Joanne Haviland
@nl
Joanne Haviland
@sl
type
label
Joanne Haviland
@ast
Joanne Haviland
@en
Joanne Haviland
@es
Joanne Haviland
@nl
Joanne Haviland
@sl
prefLabel
Joanne Haviland
@ast
Joanne Haviland
@en
Joanne Haviland
@es
Joanne Haviland
@nl
Joanne Haviland
@sl
P108
P106
P108
P21
P31
P496
0000-0001-5728-3636